Clinical trials: ACS
Myocardial Infarction, Acute Coronary Syndrome
Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use
Cocaine use has increased in our country in recent decades. It is associated with cardiovascular events and early atherosclerotic disease. Acute coronary syndrome (ACS) is one of its most frequent and serious manifestations.
- Conditions
- Myocardial Infarction, Acute Coronary Syndrome, Cocaine Use, Cocaine Abuse
- Trial name
- NCT06177860
- Where
- Argentina
- Volunteers
- 400 people
- Sponsor
- Hospital El Cruce
Alzheimer Disease
Imaging Biomarkers in Preclinical and Symptomatic AD
The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD.
- Trial name
- ACS_PIB_IND (NCT04134923)
- Testing
- [11C] Pittsburgh Compound-B (PIB)
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer
The study main objectives are to enhance treatment decision making and improve quality of life and post-treatment health care among patients diagnosed with invasive bladder cancer.
- Trial name
- NCT01915121
- Testing
- Education Intervention, Nutrition Intervention
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Non ST Elevation Myocardial Infarction
Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up
1. INTRODUCTION Through last couple of years the number of patients treated for acute coronary event without persistent ST segment elevation in ECG has been growing.
- Trial name
- NCT01863134
- Testing
- Eptifibatide
- Where
- 6 sites in United States, Poland
- Volunteers
- 140 people
- Sponsor
- Medical University of Silesia
Thoracic
Validation of ACS NSQIP Risk Calculator for Predicting Complications After Thoracic Surgery at University Hospital Basel
This single-center retrospective research project aims to evaluate whether and what is the significance of the National Surgical Quality Improvement Program of the American College of Surgeons (ACS NSQIP) risk score in thoracic…
- Trial name
- NCT06483464
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- University Hospital, Basel, Switzerland
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Acute Coronary Syndrome, Myocardial Infarction
Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Smoking
- Trial name
- ZESCA (NCT00689611)
- Testing
- Bupropion HCl ER
- Where
- 38 sites in United States, Bangladesh and 5 more
- Volunteers
- 392 people
- Sponsor
- Mark Eisenberg
Acute Coronary Syndrom, Chronic Obstructive Pulmonary Syndrom
Pneumological Acute Coronary Syndrom (ACS) Phenotyping Aachen
In this open, monocentric, observational study acute coronary syndrom (ACS) patients will be characterized by pneumological examination concerning a concomitant chronic obstructive pulmonary disease (COPD).
- Trial name
- PAPA (NCT02587481)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- RWTH Aachen University
Twin Pregnancy, Antepartum Condition or Complication
Effects of ACS in Twin With LPB: Study Protocol for a RCT
This study will be the first study that evaluates the effectiveness of antenatal corticosteroid (ACS) in late preterm twin neonates.
- Trial name
- NCT03547791
- Testing
- Betamethason Sodium Phosphate, Normal saline
- Where
- South Korea
- Volunteers
- 848 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
The aim of this clinical trial is to investigate whether dapagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) can reduce levels of coronary inflammation in patients with stage 4 CKM syndrome.
- Trial name
- DAPA-PCAT (NCT07351643)
- Testing
- Dapagliflozin
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shenyang Northern Hospital
Acute Coronary Syndrome (ACS)
Self-Management Support for Acute Coronary Syndrome Patients After Hospital Discharge
This randomized controlled trial evaluates a "Hospital-to-Home" self-management support model for Acute Coronary Syndrome (ACS) patients, which is based on the integrated COM-B and HAPA theories.
- Trial name
- ACS (NCT07799376)
- Testing
- COM-B and HAPA-based Self-management Support Program, Routine Health Education
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Acute Coronary Syndromes, Secondary Prevention
triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
Early and intensive LDL-cholesterol (LDL-c) reduction is associated with improved short-term and long-term outcomes. Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers LDL-c upstream of HMG-CoA reductase.
- Conditions
- Acute Coronary Syndromes, Secondary Prevention, Lipids
- Trial name
- PERSUADE (NCT07440381)
- Testing
- Triple oral lipid lowering treatment
- Where
- 35 sites in Italy
- Volunteers
- 600 people
- Sponsor
- Heart Care Foundation
Acute Coronary Syndrome
Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia.
- Trial name
- Zeus-ACS (NCT00514501)
- Testing
- Iodofiltic acid I 123
- Where
- 38 sites in United States, Canada
- Volunteers
- 510 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome, Atrial Fibrillation
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
The selection of the optimal antithrombotic therapy in patients with nonvalvular atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is challenging.
- Trial name
- EPIDAURUS (NCT04981041)
- Testing
- Prasugrel or Ticagrelor, Clopidogrel
- Where
- 37 sites in Austria, Germany
- Volunteers
- 602 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Myocardial Infarction (MI), Acute Coronary Syndrome (ACS)
Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction
The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with…
- Trial name
- TITAN-OMI (NCT07077057)
- Testing
- AI-assisted ECG interpretation (PMcardio)
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Cardiocentro Ticino
Acute Coronary Syndrome
Efficacy and Safety Study of Ticagrelor
The purpose of this study is to compare the efficacy and safety of ticagrelor with clopidogrel
- Trial name
- NCT01812330
- Testing
- Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 180 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
NAFLD, ACS - Acute Coronary Syndrome
Prevalence of NAFLD in ACS Patients
Addressing CVD risk in patients with NAFLD is the aspect of the disease most amenable to medical management and so improving long-term clinical outcomes.
- Trial name
- PADAC (NCT05378321)
- Testing
- Non-invasive diagnostic testing
- Where
- Belgium
- Volunteers
- 225 people
- Sponsor
- Ziekenhuis Oost-Limburg
Acute Coronary Syndrome
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE (NCT02525939)
- Testing
- dalcetrapib
- Where
- 557 sites in United States, Argentina and 30 more
- Volunteers
- 6,147 people
- Sponsor
- DalCor Pharmaceuticals